Gone again in Sweden, as I read the proxy statement it is obvious that the new company will have to have income immediately or big investors just to cover the salaries of Dr. Teper and the other members of the board, I still think Amiket is a done deal, if it is not, then something in the pipeline will have to generate some interest and cash or the new company will not be around long. Keep praying for some positive news before the merger happens.
I guess it depends on what kind of shape Immune is in. I would certainly hope that they wouldn't have taken Epicept on if they did think they couldn't get Amiket approved and on the market ASAP. I'm assuming they bet Amiket will be a cash cow. Everything else in the pipeline seems like it is still going to require an awful lot of capital. So, regardless of Amiket, I think it's still a long time before the new company is profitable, but I am optimistic about its future.